Answers are grounded in this paper and cite their sources.
Background Sacituzumab govitecan (SG) is approved in Japan for pretreated unresectable or recurrent triple-negative breast cancer (TNBC). ASCENT-J02 is an open-label, phase 1/2 study of SG in Japanese patients. At primary analysis (median follow-up, 6.1 months) of the metastatic TNBC (mTNBC) cohort ( n = 36), objective response rate (ORR) was 25.0% (95% CI: 12.1–42.2; P = 0.0077), median progression-free survival (PFS) was 5.6 months (95% CI: 3.9–not reached), and SG had a manageable safety profile, consistent with the global phase 3 ASCENT study. We report updated outcomes, including the first overall survival (OS) results. Methods Patients with pretreated mTNBC received 10 mg/kg SG intravenously on days 1 and 8 of 21-day cycles. The primary endpoint was independent review committee-assessed ORR (RECIST v1.1). Secondary endpoints included PFS, duration of response, time to response, OS, and safety. Results With median follow-up of 15.9 months for 36 patients with mTNBC, ORR with SG was 31% (95% CI: 16–48); four complete responses were observed. Median PFS was 5.6 months (95% CI: 3.9–15.8), and median OS was 15.9 months (95% CI: 10.4–22.4). No treatment-emergent adverse events (TEAEs) led to treatment discontinuation or death. Grade ≥ 3 TEAEs were observed in 26 (72%) patients; most frequent were neutropenia (58%), leukopenia (36%), and diarrhea (11%). Conclusions With longer follow-up, SG continued to demonstrate efficacy and safety consistent with the global ASCENT study. These results further support the use of SG in Japanese patients with pretreated mTNBC.
No takes yet. Share an insight, caveat, or question.
Kawaguchi‐Sakita et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: